Because it was thought that a study of the demonstrable phenomena of immunity of the host which accompany recovery from pneumococcic infections provided an approach to rational therapeutic procedure, such phenomena were the chief concern of investigators prior to the introduction of sulfapyridine (2-[paraaminobenzenesulfonamido]-pyridine). Ever since the drug has been therapeutically employed attention has shifted to the infecting organism and emphasis has been placed on the mechanism of bacteriostasis. At present, attention is again directed to the humoral recovery mechanisms in relation to the action of sulfanilamide and its derivatives. Whitby found that sulfapyridine did not affect the quality, quantity or speed of production of antibodies. It has been observed that many patients who recover from pneumococcic pneumonia under treatment with sulfapyridine do so without any detectable circulating antibodies having developed. Results of adequate investigation of the possible complementary activity of the drug and of the antibody have not been
BULLOWA JGM, de GARA PF, BUKANTZ SC. TYPE-SPECIFIC ANTIBODIES IN THE BLOOD OF PATIENTS WITH PNEUMOCOCCIC PNEUMONIA: DETECTION, INCIDENCE, PROGNOSTIC SIGNIFICANCE AND RELATION TO THERAPIES. Arch Intern Med (Chic). 1942;69(1):1–14. doi:10.1001/archinte.1942.00200130009001
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.